Adverse events associated with smallpox vaccination in the United States, January-October 2003.
about
Smallpox vaccines for biodefense: need and feasibilityWhat Is the Arrhythmic Substrate in Viral Myocarditis? Insights from Clinical and Animal StudiesProspective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic reviewEstimating the Size of the U.S. Population at Risk of Severe Adverse Events from Replicating Smallpox Vaccine.Finding and removing highly connected individuals using suboptimal vaccines.Demographic and clinical factors associated with response to smallpox vaccine in preimmunized volunteersComparison of smallpox outbreak control strategies using a spatial metapopulation model.Smallpox transmission and control: spatial dynamics in Great Britain.Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccineSafety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapyA quantitative rabbit model of vaccinia keratitis.Evaluation of therapeutic interventions for vaccinia virus keratitisDeletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switchingCountermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications.Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection.A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.Adversomics: a new paradigm for vaccine safety and design.Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigensVaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms.Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.Antibody responses to vaccinia membrane proteins after smallpox vaccination.Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypoxSafety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeuticsThe strategic use of novel smallpox vaccines in the post-eradication world.Unintentional transfer of vaccinia virus associated with smallpox vaccines: ACAM2000(®) compared with Dryvax(®).Ischemic cardiac events and other adverse events following ACAM2000(®) smallpox vaccine in the Vaccine Adverse Event Reporting System.Vaccinia virus A35R inhibits MHC class II antigen presentation.Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II.Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma.Genomic identification of human vaccinia virus keratoconjunctivitis and its importance as a laboratory-acquired infection.Vaccination-Related Side Effects, Humoral Immunity, and Adverse Events during the Civilian Smallpox Vaccination Campaign, Arkansas, 2003.Poxvirus countermeasures during an emergency in the United States.Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide.Long-term T cell memory to human leucocyte antigen-A2 supertype epitopes in humans vaccinated against smallpox.
P2860
Q22305942-C1D446C0-1C0E-495F-AD45-7400E83D6A6CQ26738973-61EB5546-4D01-4B53-9622-809BA1042C2CQ28485174-D847B345-4F0F-47DE-A56E-9542B320D91DQ30151714-B5AD1F46-F9AF-488C-B64F-920979F0B766Q30224717-F06D3BBA-3BC4-4C80-8738-603F83181E2BQ30228332-C7EE8F32-03F2-4668-8208-CF58175E505DQ30230157-4BDEFDB6-0630-49BB-95E4-E80C8EF07253Q30477988-51E0356E-E7BA-44B0-9EA6-7A6D42F1B92AQ30977303-1EB87BDC-E2A3-4B9F-972E-A0DD999BA206Q33729509-5153BCC6-BAF0-4767-81AE-1FA1C95A7727Q33754697-758672CF-8A9F-45E7-811B-1883112BDF39Q34135490-E47EE7ED-98E5-4E48-9D62-39E3B89E255AQ34772694-2B56E4D7-A2FD-4FEF-BF27-30A84E4623AAQ34810232-24533811-1B2B-4089-ABE3-F5A63699D2ACQ35166824-7F3DE8E4-5F1D-4CD7-A551-2BF67234806DQ35557123-A134301E-51F1-4BAD-A111-C42933B481ADQ35571248-D750DC84-7858-4110-85E9-090A9C4C0FB4Q35826728-AA6D1BA8-9D83-4AB4-839F-70FF638102B6Q35830974-2B5568E3-C496-44AC-AD47-775366B9DD4FQ36057928-2D7C41D5-E97B-4B77-ADC2-3EC198814392Q36242667-6ACB7CB7-DC4B-4F43-91F0-93014A704858Q36477717-22DE5139-A8C1-46BC-B5D6-09A4A8C3A62BQ36488876-1D459D1A-CF05-4002-8C33-39D8A366D901Q36599215-665211AF-C322-48EC-8067-F21E93837E89Q36747784-673DD166-EEDB-49A0-88D5-86BE7D109AFCQ36845650-392CCD74-5731-483B-B734-D5DA0FDCF2A3Q36869365-4C63F2BD-07AC-4C92-96BD-485E29B25893Q37033408-A73A1586-CE39-4A67-8700-316DEA25B060Q37191938-621B0C3D-36D6-4607-9C1A-E1F0039FA744Q37909421-AEDE9DF7-F325-44B0-BC5F-AC55A66D0F9CQ38097615-6C3AA224-B4D9-4192-8DD5-94D102171F49Q38222113-2D0B8362-1E62-4D1B-ABE8-5FC42F1E968CQ39390434-BF1FA79D-EA2A-40D2-94BB-761A2E8CF870Q39753158-23E246DC-29FA-4043-9F74-771B3946C278Q40083001-BA4172F3-4A71-4110-9E95-4CAA718FDEB1Q40348698-FDF8B174-E09B-4853-8A11-AC963D184FFAQ40869018-118DA955-B372-4783-9FD3-24053B51B625Q41681967-A38A6E36-97C0-4501-87E3-6EBE37F90397Q42143723-8065634A-98F1-45E6-983C-E1121783A890Q42619783-EE3C8519-7682-496A-B0FC-0953338B8393
P2860
Adverse events associated with smallpox vaccination in the United States, January-October 2003.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Adverse events associated with ...... States, January-October 2003.
@ast
Adverse events associated with ...... States, January-October 2003.
@en
type
label
Adverse events associated with ...... States, January-October 2003.
@ast
Adverse events associated with ...... States, January-October 2003.
@en
prefLabel
Adverse events associated with ...... States, January-October 2003.
@ast
Adverse events associated with ...... States, January-October 2003.
@en
P2093
P356
P1476
Adverse events associated with ...... States, January-October 2003.
@en
P2093
Charles Vitek
Christine G Casey
Claudia Vellozzi
Eric E Mast
Gina Mootrey
Inger Damon
James D Heffelfinger
John K Iskander
Juliette Morgan
La Mar Hasbrouck
P304
P356
10.1001/JAMA.294.21.2734
P407
P577
2005-12-01T00:00:00Z